0013.HK

HUTCHMED (China) Limited [0013.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

0013.HK Stock Summary

Earnings have grown 96.52% per last year.

EPS has increased from the previous year and become positive (Yearly statements)

Earnings are expected to fall -100% next year

Profit margins (-0.96%) are lower than the previous year (0.12%)

0013.HK has less than 1 year of cash runway

Top 10 Correlated ETFs

0013.HK

Top 10 Correlated Stocks

0013.HK

In the News

0013.HK Financial details

Company Rating

Buy

Market Cap

25.22B

Income

-29.42M

Revenue

757.24M

Book val./share

Cash/share

Dividend

Dividend %

Employees

1.99K

Optionable

Shortable

Yes

Earnings

29 Feb 2024

P/E

-6.67

Forward P/E

PEG

0.74

P/S

6.6

P/B

4.48

P/C

P/FCF

-9.21

Quick Ratio

1.78

Current Ratio

2.37

Debt / Equity

0.12

LT Debt / Equity

0.07

EPS (TTM)

-0.05

EPS next Y

EPS next Q

EPS this Y

-125%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

32.54%

Revenue Q/Q

EPS Q/Q

SMA20

7.9%

SMA50

34.48%

SMA100

-5.9%

Inst Own

Inst Trans

ROA

-40%

ROE

-51%

ROC

-0.61%

Gross Margin

27%

Oper. Margin

-96%

Profit Margin

-96%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

17.44-33.8

52W High

-19.55%

52W Low

+56.18%

RSI

48.89

Rel Volume

0.73

Avg Volume

3.61M

Volume

2.64M

Perf Week

-1.12%

Perf Month

10.17%

Perf Quarter

-0.93%

Perf Half Y

-8.29%

Beta

0.679

Volatility

0.97%, 1.78%

Prev Close

-0.38%

Price

26.55

Change

-4.84%

0013.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.31	0.33	0.45	0.5	0.99
Net income per share	-0.22	-0.28	-0.29	-0.48	0.12
Operating cash flow per share	-0.12	-0.09	-0.26	-0.32	0.26
Free cash flow per share	-0.13	-0.12	-0.28	-0.36	0.22
Cash per share	0.33	0.62	1.28	0.74	1.04
Book value per share	0.43	0.69	1.25	0.72	0.86
Tangible book value per share	0.46	0.74	1.31	0.75	0.87
Share holders equity per share	0.43	0.69	1.25	0.72	0.86
Interest debt per share	0.05	0.05	0.04	0.03	0.1
Market cap	5.15B	5.43B	5.74B	2.6B	3.05B
Enterprise value	5.06B	5.23B	5.4B	2.31B	2.85B
P/E ratio	-35.67	-27.89	-25.21	-6.35	30.27
Price to sales ratio	25.14	23.8	16.11	6.11	3.64
POCF ratio	-63.65	-87.43	-28.1	-9.7	13.91
PFCF ratio	-57.56	-66.46	-25.97	-8.53	16.34
P/B Ratio	17.88	11.21	5.82	4.27	4.18
PTB ratio	17.88	11.21	5.82	4.27	4.18
EV to sales	24.71	22.93	15.15	5.43	3.4
Enterprise value over EBITDA	-37.46	-28.58	-16.39	-5.77	42.41
EV to operating cash flow	-62.56	-84.21	-26.42	-8.62	13.01
EV to free cash flow	-56.57	-64.01	-24.42	-7.58	15.29
Earnings yield	-0.03	-0.04	-0.04	-0.16	0.03
Free cash flow yield	-0.02	-0.02	-0.04	-0.12	0.06
Debt to equity	0.11	0.07	0.03	0.04	0.12
Debt to assets	0.07	0.05	0.02	0.03	0.07
Net debt to EBITDA	0.65	1.09	1.04	0.72	-2.94
Current ratio	2.8	3.35	3.89	2.37	2.72
Interest coverage	-140.8	-240.09	-568.34	-628.48	77.82
Income quality	0.78	0.54	1.22	0.75	2.17
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.19	0.22	0.25	0.22	0.1
Research and developement to revenue	0.45	0.49	0.58	0.63	0.36
Intangibles to total assets	0.01	0	0	0	0.47
Capex to operating cash flow	0.11	0.32	0.08	0.14	-0.15
Capex to revenue	-0.04	-0.09	-0.05	-0.09	-0.04
Capex to depreciation	-1.73	-3.23	-2.33	-4.23	-3.97
Stock based compensation to revenue	0.06	0.09	0.12	0.07	0.04
Graham number	1.45	2.09	2.84	2.8	1.51
ROIC	-0.45	-0.37	-0.35	-0.64	0.07
Return on tangible assets	-0.31	-0.27	-0.17	-0.4	0.15
Graham Net	0.16	0.4	0.96	0.4	0.44
Working capital	203.92M	372.34M	900.42M	485.99M	693.81M
Tangible asset value	309.52M	515.42M	1.04B	636.87M	140.64M
Net current asset value	164.8M	325.57M	878.93M	447.31M	560.45M
Invested capital	0.11	0.07	0.03	0.04	0.12
Average receivables	21.63M	45.56M	65.73M	90.78M	48.99M
Average payables	24.79M	27.79M	36.39M	56.15M	53.72M
Average inventory	14.26M	17.99M	27.76M	46.22M	53.47M
Days sales outstanding	77.05	76.64	85.66	83.88	0
Days payables outstanding	54.61	61.21	58.2	83.44	34.49
Days of inventory on hand	36.94	38.27	50.54	66.51	47.72
Receivables turnover	4.74	4.76	4.26	4.35	0
Payables turnover	6.68	5.96	6.27	4.37	10.58
Inventory turnover	9.88	9.54	7.22	5.49	7.65
ROE	-0.5	-0.4	-0.23	-0.67	0.14
Capex per share	-0.01	-0.03	-0.02	-0.04	-0.04

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.13	0.13	0.3	0.3	0
Net income per share	-0.12	-0.12	0.1	0.1	0
Operating cash flow per share	-0.11	-0.11	0.13	0.13	0
Free cash flow per share	-0.12	-0.12	0.11	0.11	0
Cash per share	0.76	0.75	0.97	0.97	0
Book value per share	0.73	0.73	0.88	0.88	0
Tangible book value per share	0.76	0.76	0.9	0.9	0
Share holders equity per share	0.73	0.73	0.88	0.88	0
Interest debt per share	0.02	0.03	0.05	0.05	0
Market cap	1.41B	2.58B	2.33B	2.09B	0
Enterprise value	1.1B	2.29B	2.11B	1.9B	-197.46M
P/E ratio	-3.57	-6.51	6.92	6.19	0
Price to sales ratio	12.59	22.98	8.76	7.83	0
POCF ratio	-15.81	-28.85	20.62	18.43	0
PFCF ratio	-14.15	-25.83	23.1	20.66	0
P/B Ratio	2.31	4.22	2.98	2.67	0
PTB ratio	2.31	4.22	2.98	2.67	0
EV to sales	9.8	20.4	7.92	7.15	0
Enterprise value over EBITDA	-10.64	-22.15	36.56	32.98	0
EV to operating cash flow	-12.3	-25.61	18.65	16.82	0
EV to free cash flow	-11.01	-22.92	20.89	18.85	0
Earnings yield	-0.07	-0.04	0.04	0.04	0
Free cash flow yield	-0.07	-0.04	0.04	0.05	0
Debt to equity	0.03	0.04	0.05	0.05	0.12
Debt to assets	0.02	0.03	0.03	0.03	0.07
Net debt to EBITDA	3.03	2.81	-3.86	-3.17	0
Current ratio	2.37	2.37	3.2	3.2	2.72
Interest coverage	0	0	0	0	0
Income quality	0.9	0.9	1.34	1.34	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.15	0.15	0.08	0.08	0
Research and developement to revenue	0.91	0.91	0.27	0.27	0
Intangibles to total assets	0	0	0	0	0.47
Capex to operating cash flow	0.12	0.12	-0.11	-0.11	0
Capex to revenue	-0.09	-0.09	-0.05	-0.05	0
Capex to depreciation	-4.88	-4.88	-6.39	-6.39	0
Stock based compensation to revenue	0.07	0.07	0.03	0.03	0
Graham number	1.39	1.39	1.37	1.37	0
ROIC	-0.17	-0.17	0.07	0.07	0
Return on tangible assets	-0.1	-0.1	0.06	0.06	0
Graham Net	0.41	0.41	0.55	0.54	0
Working capital	485.99M	485.99M	749.62M	749.62M	693.81M
Tangible asset value	636.87M	636.87M	800.02M	800.02M	140.64M
Net current asset value	447.31M	447.31M	593.01M	593.01M	560.45M
Invested capital	0.03	0.04	0.05	0.05	0.12
Average receivables	87.53M	97.99M	113.6M	129.2M	0
Average payables	61.06M	71.12M	62.85M	54.58M	0
Average inventory	51.31M	56.69M	55.28M	53.88M	0
Days sales outstanding	78.61	78.61	43.64	43.64	0
Days payables outstanding	33.78	33.78	27.83	27.83	0
Days of inventory on hand	26.93	26.93	27.48	27.48	0
Receivables turnover	1.14	1.14	2.06	2.06	0
Payables turnover	2.66	2.66	3.23	3.23	0
Inventory turnover	3.34	3.34	3.28	3.28	0
ROE	-0.16	-0.16	0.11	0.11	0
Capex per share	-0.01	-0.01	-0.01	-0.01	0

0013.HK Frequently Asked Questions

What is HUTCHMED (China) Limited stock symbol ?

HUTCHMED (China) Limited is a HK stock and trading under the symbol 0013.HK

What is HUTCHMED (China) Limited stock quote today ?

HUTCHMED (China) Limited stock price is $26.55 today.

Is HUTCHMED (China) Limited stock public?

Yes, HUTCHMED (China) Limited is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 3.61M
Market Capitalization 25.22B
Employee 1.99K
CEO Dr. Wei-Guo Su B.Sc., Ph.D.
Headquarters Central,HK
IPO Date 2021-06-30
Website https://www.hutch-med.com

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.